Background {#Sec1}
==========

The Study for Monitoring Antimicrobial Resistance Trends (SMART) is a global surveillance program, which monitors annually in vitro antimicrobial susceptibilities of hospital acquired (HA) and community acquired (CA) intra-abdominal and urinary tract infections due to aerobic and facultative Gram-negative bacilli (GNB). Intra-abdominal infections (IAIs) are the second most common cause of sepsis in intensive care units (ICU) \[[@CR1]\] where they are the second most common cause of infection-related mortality \[[@CR2]\]. IAIs are also the second most common cause of infection related to surgical interventions and according to a multicenter observational study in 68 medical institutions worldwide, \[[@CR3]\] the overall mortality rate of patients with complicated IAIs in 2012--2013 was 10.5%, \[[@CR4]\], with ESBL producing bacteria being a particular challenge for treatment \[[@CR5]\]. However, initiation of appropriate antimicrobial therapy can significantly reduce the mortality rate of IAI-induced septic shock \[[@CR6]\]. Since appropriate antibiotic therapy is essential for IAIs \[[@CR7], [@CR8]\], institutional and nationwide surveillance of IAI-derived bacterial strain susceptibilities provides crucial information for the selection of the right choice of empirical antimicrobial treatment.

Although a significant increase of the proportion of ESBL-positive *Enterobacteriaceae* hospital infections in Germany over the period 2007--2012 \[[@CR9]\] and in Japan from 2000 to 2010 have been reported \[[@CR10], [@CR11]\] the situation in China is not clear. A limited number of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* IAI isolates from 2012 and 2013 have been documented, but there is a wide diversity in ESBL-related molecular characteristics \[[@CR12]\].

The present study mainly focused on ESBL-screen positive rates of IAI isolates and concomitantly on resistance rates of IAIs, in particularly those caused by *Enterobacteriaceae* against, 3rd and 4th generation cephalosporins, a cephamycin, 2nd generation fluoroquinolones, carbapenems, an aminoglycoside, as well as a combination of drugs containing [penicillin](https://en.wikipedia.org/wiki/Penicillin)s with [β-lactamase](https://en.wikipedia.org/wiki/Beta-lactamase) inhibitors. The data was collected from 21 centers in 16 Chinese cities between 2012 and 2014 in order to provide guidance for antimicrobial therapy of IAIs.

Methods {#Sec2}
=======

Collection and identification of isolates {#Sec3}
-----------------------------------------

The Human Research Ethics Committee of Peking Union Medical College Hospital approved this study and waived the need for consent (Ethics Approval Number: S-K238).

GNB strains were collected from consecutive IAI patients between 2012 and 2014 in 21 centers located in 16 Chinese cities. Only gram-negative aerobic and facultative anaerobic bacteria from abdominal infection sites such as the appendix, peritoneum, colon, bile, pelvis and pancreas were included and the strains needed to be pathogenic bacteria associated with clinical infections while gram-positive and anaerobic bacteria were excluded. The specimens were mainly obtained through surgical procedures, but puncture specimens such as intraperitoneal puncture fluid were also included and different gram-negative bacteria that were combined in one sample were also accepted. Exclusion criteria were isolates from drainage liquid or drainage bottles, as well as isolates from feces or perianal abscess environmental samples (not a patient source) or cultures for infection control purposes. All isolates were sent to the central clinical microbiology laboratory of Peking Union Medical College Hospital for initial bacteria identification and re-identification using MALDI-TOF MS (Vitek MS, BioMérieux, France). All organisms were considered clinically significant by local hospital criteria. Isolates collected within 48 h of hospitalization were categorized as CA IAIs, and those collected after 48 h were categorized as HA IAIs \[[@CR13]\].

Antimicrobial susceptibility test method {#Sec4}
----------------------------------------

All isolate susceptibility tests and identification confirmations were carried out by the Clinical and Laboratory Standards Institute (CLSI) recommended broth microdilution method. Minimum inhibitory concentrations (MICs) interpretive criteria followed the 2014 M100-S24 guidelines of the CLSI. M100-S23 criteria were used to maintain the intermediate category for analysis \[[@CR14]\]. Susceptibility to antimicrobial agents interpretations were based on clinical CLSI breakpoints, while the reference strains *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853 and *Klebsiella pneumoniae* ATCC 700603 were used as quality controls. Twelve antimicrobial agents were used for susceptibility tests in the present study, namely ceftriaxone (CRO), ceftazidime (CAZ), cefotaxime (CTX), cefepime (FEP), cefoxitin (FOX), ertapenem (ETP), imipenem (IPM), ampicillin-sulbactam (SAM), piperacillin-tazobactam (TZP), ciprofloxacin (CIP), levofloxacin (LVX) and amikacin (AMK).

Extended-spectrum β-lactamase (ESBL) detection {#Sec5}
----------------------------------------------

Phenotypic identification of ESBL-screen positivity in *Escherichia coli* and *Klebsiella pneumoniae* (ESBL+) were carried out by CLSI recommended methods \[[@CR15]\]. If cefotaxime or ceftazidime MICs were ≥2 μg/mL, the MICs of cefotaxime + clavulanic acid (4 μg/mL) or ceftazidime + clavulanic acid (4 μg/mL) were comparatively determined and ESBL production was defined as a ≥ 8-fold decrease in MICs for cefotaxime or ceftazidime tested in combination with clavulanic acid, compared to their MICs without clavulanic acid.

Statistical analysis {#Sec6}
--------------------

All of the statistical analyses were performed using the IBM SPSS Statistics for Windows (Version 19.0. Armonk, NY: IBM Corp). The susceptibility of all Gram-negative isolates combined was calculated using breakpoints appropriate for each species and assuming 0% susceptible for species with no breakpoints for any given drug. The 95% confidence intervals were calculated using the adjusted Wald method; linear trends in susceptibility and ESBL rates were assessed for statistical significance using the Cochran-Armitage test; *P* values \<0.05 were considered to be statistically significant.

Results {#Sec7}
=======

Basic information on IAI isolates collected from 2012 to 2014 {#Sec8}
-------------------------------------------------------------

From the included 5160 GNB strains (1917 strains were collected in 2012, 1665 strains in 2013, and 1578 strains in 2014), the majority (79.8--83.8%) belonged to *Enterobacteriaceae* including *Escherichia coli* (45.4% of all GNBs), *Klebsiella pneumoniae* (20.1% of all GNBs), followed by *Enterobacter cloacae* (5.2%), *Proteus mirabilis* (2.1%), *Citrobacter freundii* (1.8%), *Enterobacter aerogenes* (1.8%), *Klebsiella oxytoca* (1.4%), *Morganella morganii* (1.2%), *Serratia marcescens* (0.7%), *Citrobacter koseri* (0.3%), *Proteus vulgaris* (0.3%) and others 1.0%. Non-*Enterobacteriaceae* were isolated from 16.2--20.2% of all GNB caused IAIs and included *Pseudomonas aeruginosa* (9.8%), *Acinetobacter baumannii* (6.7%), *Stenotrophomonas maltophilia* (0.9%), *Aeromonas hydrophila* (0.4%) and others (1.1%) (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Overall susceptibilities of the 5160 IAIs to the 12 antimicrobial agents tested in the study are shown in Table [1](#Tab1){ref-type="table"}. Highest overall susceptibilities of the 5610 GNB isolates from IAIs between 2012 and 2014 were found to amikacin (87.53%), imipenem (81.41%), piperacillin tazobactam (78.12%) and ertapenem (73.12%). Susceptibilities to all tested cephalosporins, fluoroquinolones and ampicillin sulbactam were between 22.24% and 58.75%.Table 1Susceptibilities of all 5160 included strains derived from Chinese IAIs from 2012 to 2014 to 12 tested antibioticsPercent Susceptibilities201220132014SumAmikacin87.2089.1686.2287.53Piperacillin Tazobactam76.7781.8575.7578.12Ampicillin Sulbactam18.7024.7223.3022.24Imipenem80.6684.2679.3081.41Ertapenem73.1875.7170.4873.12Cefoxitin50.0055.5252.3852.64Ceftazidime54.8061.7759.6958.75Cefepime43.6751.9251.0548.88Ceftriaxone31.2536.7438.6635.55Cefotaxime30.9836.4937.4634.98Levofloxacin49.6353.9055.6253.05Ciprofloxacin45.5248.2050.3548.02

The relative percentages of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* strains from IAI isolates showed a decreasing trend from 2012 to 2014 for *Klebsiella pneumoniae* (*P* = 0.021) and for *Escherichia coli* (67.5% to 58.9%), though not significant for the later one (Table [2](#Tab2){ref-type="table"}).Table 2ESBL-screen positive strain percentages of HA and CA derived from IAIs (n/n, %)Organism2012\
*N* (%)2013\
*N* (%)2014\
*N* (%)Total\
*N* (%)*P-*valueESBL+ strains in IAIsTotal767/1917 (40.0)626/1665 (37.6)^a^507/1578 (32.1)^a^1900/5160 (36.8)^a^0.0038CA166/465 (35.7)121/375 (32.3)204/598 (34.1)491/1438 (34.1)0.7651HA601/1452 (41.4)503/1277 (39.4)295/959 (30.8)1399/3688 (37.9)0.0011*E. coli* ESBL+Of all *E. coli*Total599/887 (67.5)469/772 (60.8)^a^403/684 (58.9)^a^1471/2343 (62.8)^a^0.1978CA138/234 (59.0)99/192 (51.6)162/269 (60.2)399/695 (57.4)0.5920HA461/653 (70.6)368/575(64.0)236/406 (58.1)1065/1634 (65.2)0.1528Of all ESBL+ IAI isolates599/767 (78.1)469/626 (74.9)403/507 (79.5)1471/1900 (77.4)0.7905*K. pneumoniae* ESBL+Of all *K. pneumoniae*Total136/337 (40.4)145/381 (38.1)85/319 (26.6)^a^366/1037 (35.3)^a^0.0215CA27/87 (31.0)21/85 (24.7)33/112 (29.5)81/284 (28.5)0.7703HA109/250 (43.6)124/295 (42.0)49/201 (24.4)282/746 (37.8)0.0060Of all ESBL+ IAI isolates136/767 (17.7)145/626 (23.2)85/507 (16.8)366/1900 (19.3)0.0448*P. mirabilis* ESBL+Of all *P. mirabilis*Total24/48 (50.0)8/32 (25.0)12/29 (41.4)44/109 (40.4)0.3265CA0/11 (0.0)1/10 (10.0)3/9 (33.3)4/30 (13.3)0.1680HA24/37 (64.9)7/22 (31.8)9/20 (45.0)40/79 (50.6)0.3411Of all ESBL+ IAI isolates24/767 (3.1)8/626 (1.3)12/507 (2.4)44/1900 (2.3)0.1715*K. oxytoca* ESBL+Of all *K. oxytoca*Total8/21 (38.1)4/18 (22.2)7/31 (22.6)19/70 (27.1)^a^0.6073CA1/3 (33.3)0/5 (0)6/19 (31.6)7/27 (25.9)0.4672HA7/18 (38.9)4/12 (33.3)1/12 (8.3)12/42 (28.6)0.3426Of all ESBL+ IAI isolates8/767 (1.0)4/626 (0.6)7/507 (1.4)19/1900 (1.0)0.4608Note: *Escherichia coli* (*E. coli*), *Klebsiella pneumoniae* (*K. pneumoniae*), Hospital Acquired (HA), Community Acquired (CA)^a^indicates that few strains were not categorized into HA and CA IAIs

Of all ESBL-screen positive bacterial strains isolated from IAIs (1900), *Escherichia coli* ESBL+ strains were the most frequently isolated (74.9--79.5% of all ESBL+ IAIs), followed by *Klebsiella pneumoniae* (16.8--23.2% of all ESBL+ IAIs) and *Proteus mirabilis* (1.3--3.1% of all ESBL+ IAIs) with the least frequent isolated ESBL+ strain being *Klebsiella oxytoca* with only 0.6--1.4% of all ESBL producing strains isolated from IAIs between 2012 and 2014. The overall percentages of ESBL production in the *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* and *Klebsiella oxytoca* IAI strains was 36.8% with fairly constant rates for *Escherichia coli*, *Proteus mirabilis* and *Klebsiella oxytoca,* but a significant decrease of ESBL producing HA *Klebsiella pneumoniae* strains during this period (from 43.6% and 42.0% in 2012 and 2013 to 24.4% in 2014), which also reflected in a significant overall ESBL+ reduction in *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* and *Klebsiella oxytoca* IAI isolates from 40.0% in 2012 to 37.6% in 2013 and to 32.1% in 2014 (*P* = 0.0038) and the overall ESBL+ production changes of *Klebsiella pneumoniae* within the 3 year observation period (*P* = 0.0215) (Table [2](#Tab2){ref-type="table"}).

We next investigated the source of GNB strains isolated from IAIs (gall bladder, peritoneal fluid, abscess, appendix, liver and pancreas). The most frequently infected organ was the gall bladder (1072), followed by peritoneal fluid (812) and abscesses (650). The least infected organ was the pancreas (85). *Escherichia coli* infections occurred more frequently than *Klebsiella pneumoniae* infections in all organs beside the liver, in which the number of *Klebsiella pneumoniae* isolates (148) was higher than the *Escherichia coli* (88) isolates. In addition, over the three years, the highest percentages of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* occurred in pancreatic isolates*.* In accordance with the general ESBL+ percentage decrease in *Escherichia coli*, isolates from the main 6 organs collected in 2014 contained less ESBL + −producing *Escherichia coli* strains than in 2012, which occurred for *Klebsiella pneumoniae* only in gall bladder, abscess, liver and appendix infections (Additional file [2](#MOESM2){ref-type="media"}: Figure S1).

In vitro susceptibility of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* strains isolated from IAIs during 2012--2014 {#Sec9}
-------------------------------------------------------------------------------------------------------------------------------------------

Susceptibilities of ESBL-screen positive *Escherichia coli* strains were 96.66%- 98.08% to IPM, 91.26%--93.16% to ETP, 89.48%--92.75% to AMK and 84.86%- 89.34% to TZP, whereas susceptibilities to FOX was 61.60%--70.58% and varied for CAZ, LVX, CIP, FEP, SAM, CRO and CTX between 0% and 37.53%. ESBL-screen positive *Klebsiella pneumoniae* strains were 70.59%--80.15% susceptible to ETP, 80.0%--87.5% to IPM and 83.82%--87.06% to AMK as well as 53.79%--60.29% to FOX and also varied between 0% and 52.21% for CAZ, LVX, CIP, FEP, SAM,CRO and CTX within the three years of our study. The susceptibility of non-ESBL-screen positive *Escherichia coli* and non-ESBL-screen positive *Klebsiella pneumoniae* strains were (94.27%--98.55%) and (90.52%--97.65%) to IPM, (94.98%--98.55% and 90.09%--96.71%) to ETP, (97.82%-98.55%) and (92.67%-99.53%) to AMK, (91.04%--97.09%) and (89.22%--97.65%) to TZP, (82.44%--85.4%) and (79.74%--82.99%) to FOX, (56.0%- 63.27%) and (87.5%--92.27%) to LVX, (89.25%--95.27%) and 90.95%--96.24%) to CAZ, (96.06%--98.55%) and (91.38%--96.71%) to FEP, (88.53%--92.36%) and (90.09%--91.75%) to CRO, as well as (88.17%--94.18%) and (90.52%--93.18%) to CTX, whereas susceptibilities to SAM were only (39.43%--47.64%) and (68.53%--72.3%), respectively (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1In vitro antimicrobial susceptibilities of ESBL+ or non-ESBL-screen positive *Escherichia coli* strains and ESBL+ or non-ESBL-screen positive *Klebsiella pneumoniae* strains causing IAIs between 2012 and 2014

Next, we investigated local differences of susceptibilities to 12 antibiotics **(**Fig. [2](#Fig2){ref-type="fig"}) and the susceptibility rates against *Escherichia coli* and *Klebsiella pneumoniae* were essentially higher in participating centers located in the south and northeast compared to the southwest and central China. In addition, the susceptibility rates to IPM ETP AMK and TZP of *Klebsiella pneumoniae* were lowest in the centers from the east of China, indicating the development of multi-resistant strains in this region.Fig. 2Antimicrobial susceptibilities for *Escherichia coli* and *Klebsiella pneumoniae* IAI isolates from the northeastern, northern, central, eastern, southwestern and southern regions of China to the indicated antimicrobials

There was no significant difference in antimicrobial susceptibility among the *Escherichia coli* and *Klebsiella pneumoniae* IAIs producing ESBL strains between HA and CA infections. However there was a tendency that susceptibility of *Klebsiella pneumoniae* ESBL+ infections was lower in CA than in HA IAIs (Table [3](#Tab3){ref-type="table"}).Table 3The susceptibilities of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* strains isolated from HA and CA IAIs*Escherichia coli*, ESBL+*Klebsiella pneumoniae*, ESBL+HA%CA%HA%CA%Amikacin91.4689.4786.1780.25Piperacillin Tazobactam85.7388.7267.3766.67Ampicillin Sulbactam4.705.763.192.47Imipenem97.8496.7484.4080.25Ertapenem92.0291.9877.6671.61Cefoxitin65.6367.4259.5845.68Ceftazidime33.8037.0936.1725.93Cefepime4.604.768.514.94Ceftriaxone0.750.751.770.00Cefotaxime0.470.001.061.23Levofloxacin19.9122.5650.0049.38Ciprofloxacin17.0918.0436.1733.33

Discussion {#Sec10}
==========

The majority of IAI isolates collected in the participating centers consisted of *Escherichia coli* and *Klebsiella pneumoniae* which is similar with data from the 2002 to 2009 SMART study \[[@CR16]\]. However, in contrast to the 2002--2009 SMART study data, which revealed an increase particularly of ESBL-screen positive *Escherichia coli* strains from 20.8% in 2002 up to 64.9% in 2009, in the present study ESBL+ rates in *Escherichia coli* strains decreased from 67.5% in 2012 to 58.9% in 2014, which was reflected also in gall bladder, abscess, liver, peritoneal fluid, appendix and pancreas derived isolates sampled in 2014. In the present study the percentages of ESBL+ *Klebsiella pneumoniae* strains notably dropped from 40.4% in 2012 to 26.6% in 2014 (*P* = 0.0215) (Table [2](#Tab2){ref-type="table"}), which was also seen in the decreased ESBL+ percentages of isolates from the gall bladder, abscess, liver and appendix. However, the percentages of ESBL+ *Escherichia coli* (66.7%) and *Klebsiella pneumoniae* (55.6%) strains isolated from pancreas remained high in 2014. Most of the infections occurred in the gall bladder and the peritoneum, which is in accordance with previous literature, but the number of isolates from the appendix was unusually low in our study \[[@CR4], [@CR17]\]. In contrast to other organs, the number of *Klebsiella pneumoniae* liver infections exceeded those caused by *Escherichia coli*, which has also been reported in previous studies, and might be explained by cryptogenic infections with a new hypervirulent K1 *Klebsiella pneumoniae* ST23 strain, which developed in Asia and spread to Australia, European countries and the USA \[[@CR18]--[@CR20]\], while a recent report by Qu et al. (2015) et al. noted that K1 ST23 were the predominant *Klebsiella pneumoniae* liver abscess causing strains in east China \[[@CR21]\]. ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* are supposed to be susceptible to cefoxitin, but a high proportion of these isolates tested cefoxitin-resistant (Table [3](#Tab3){ref-type="table"}) and a likely explanation is that they have acquired AmpC beta-lactamases and porin loss, which has been described in a previous study about cefoxitin resistant *Klebsiella pneumoniae* strains in China, which expressed DHA-1 ß-lactamase combined with porin OmpK36 deficiency \[[@CR22]\].

The percentages of *Escherichia coli* and *Klebsiella pneumoniae* ESBL+ strains was higher in HA than in CA IAI isolates, which is in accordance with a previous Chinese SMART study by Yang et al. (2013). However, in the latter study *Escherichia coli* ESBL+ rates in CA infections constantly rose from 19.1% in 2002--2003 to 61.6% in 2010--2011, whereas in our study the *Escherichia coli* ESBL+ rates in CA IAIs were relative constant at around 60%, with a reduction to 51.6% only in 2013. In contrast, the *Escherichia coli* ESBL+ rates in HA IAIs showed a decreasing trend from 70.6% in 2012 to 58.1% in 2014 in our study, but were relative stable in the years 2006--2011 (66.7%--70.0%) \[[@CR23]\].

A more dramatic change was visible for *Klebsiella pneumoniae* ESBL+ rates in HA IAIs dropping from 43.6% in 2012 and 42.0% in 2013, which is similar to the Chinese HA values (39.4%) reported for *Klebsiella pneumoniae* IAIs in 2010--2011 \[[@CR23]\], to 24.4% in 2014 *(P* = 0.006), but in CA IAIs the *Klebsiella pneumoniae* ESBL+ rates were relatively constant (between 24.7% and 31.0%), which is somewhat higher than the 22.2% reported for CA *Klebsiella pneumoniae* IAIs in 2010--2011 \[[@CR23]\]. Taken together, the total ESBL+ rates in *Klebsiella pneumoniae* and *Escherichia coli* isolates from IAIs in our study dropped between 2012 and 2014, which was due to less ESBL+ rates in HA IAIs and rather constant percentages of CA ESBL+ *Klebsiella pneumoniae* and *Escherichia coli* IAI isolates (Table [2](#Tab2){ref-type="table"}). The decrease of ESBL+ GNBs might be explained by new restrictions for the clinical application of antimicrobial agents, which has been introduced by the Chinese ministry of health in 2012 \[[@CR24]\]. The overall susceptibilities of ESBL positive *Escherichia coli* strains was 96.77%--98.8% to IPM, 91.26%--93.16% to ETP, 89.48%--92.75% to AMK and 84.86%--89.34% to TZP, while ESBL-screen positive *Klebsiella pneumoniae* strains were 70.56% -80.15% susceptible to ETP, 80.0%--87.5% to IPM, 83.82%--87.06% to AMK and 63.53%--68.38% to TZP within the three year study. However, it is noteworthy that reduced susceptibilities of *Klebsiella pneumonia* strains to the carbapenems IPM and ETP derived from centers located in east China indicated a local carbapenem-resistance, which has also been described in other countries \[[@CR25], [@CR26]\]. Because the eastern part of China is the most developed region with the highest incomes, antimicrobial overuse \[[@CR27], [@CR28]\] might be an explanation for the carbapenem susceptibility difference in this area, which has been described also for the eastern Zhejiang Province before \[[@CR29]\]. In general a previous study noted that Chinese individuals were harboring the highest number and abundance of antibiotic resistance genes in their gut microbiota compared to Danish and Spanish individuals \[[@CR30]\], but we did not include investigations of molecular mechanisms of resistances.

All tested cephalosporins and fluoroquinolones were \<70% effective for *Escherichia coli* and \<60% for *Klebsiella pneumoniae* isolates that produced ESBLs. This finding is in agreement with previous literature that suggested that carbapenems are the best choice as empirical mono therapies, especially for complicated IAIs \[[@CR31]\], but that cephalosporins, fluoroquinolones and SAM are not ideal choices for empirical treatment of IAIs in China \[[@CR16]\]. For non-ESBL-screen positive *Escherichia coli* strains, cefoxitin, levofloxacin, ciprofloxacin and ampicillin-sulbactam, and for non-ESBL-screen positive *Klebsiella pneumoniae* strains, cefoxitin and ampicillin-sulbactam were the least effective antibiotics (Fig. [1](#Fig1){ref-type="fig"}).

Taken together, the relatively high susceptibility percentages seen for imipenem and, to a slightly lesser degree, ertapenem, against *Escherichia coli* ---whether ESBL-positive or -negative---are important considerations in China, where ESBL+ rates around 60% are seen, and many other drugs from the beta-lactam class and fluoroquinolones are no longer viable options for therapy and should be avoided unless susceptibilities to this antimicrobial agents have been confirmed. Against *Klebsiella pneumoniae*, the carbapenem activity is somewhat lower, presumably because of presence of more carbapenemases (such as KPC-2-type) in *Klebsiella pneumoniae* \[[@CR32], [@CR33]\], as well as other mechanisms that include porin loss combined with AmpC or ESBL enzymes; however, even the reduced activity of carbapenems to *Klebsiella pneumoniae* is dramatically higher than all other drugs evaluated in SMART except for amikacin and piperacillin-tazobactam. Considering the relatively high ESBL rates in China, and the low susceptibility to fluoroquinolones that are usually seen in conjunction with ESBL-positive isolates, carbapenems are among the few antimicrobial agents in China retaining sufficient in vitro activity to be considered for empiric therapy. On the other hand, it is very important to retain the activity of carbapenems, so step-down therapy to other agents should always be considered once the susceptibility of a specific pathogen is known.

A limitation of the study was that genotypic or molecular data of the strains were not included, since the SMART project does not involve these kind of analyzes.

Conclusions {#Sec11}
===========

From 2012 to 2014, a total of 5160 IAI isolates were obtained, of which 81.1% were caused by *Enterobacteriaceae* and 18.9% by non-*Enterobacteriaceae*, with *Escherichia coli* (45.4%) being the most common followed by *Klebsiella pneumoniae* (20.1%). The most common non-*Enterobacteriaceae* were *Pseudomonas aeruginosa* (9.8%) and *Acinetobacter baumannii* (6.7%). The percentages of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* strains in IAI GNB isolates showed a decreasing trend from 2012 to 2014, which can be explained by less ESBL+ percentages in strains from HA IAIs.

Susceptibility of ESBL-screen positive *Escherichia coli* strains was \>80% to imipenem, ertapenem, amikacin and piperacillin-tazobactam, while ESBL-screen positive *Klebsiella pneumoniae* strains were \>70% susceptible only to imipenem, ertapenem and amikacin.

In contrast to gall bladder, abscess, peritoneal fluid, appendix and pancreas, the percentage of *Klebsiella pneumoniae* causing liver infections was higher than that caused by *Escherichia coli*. It is noteworthy that *Klebsiella pneumoniae* and *Escherichia coli* isolates from pancreatic infections exhibited consistently high ESBL+ rates.

The apparent trend of declining percentages of ESBL-screen positive *Escherichia coli* and *Klebsiella pneumoniae* strains needs to be closely monitored.
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